ASX:PYC PYC Therapeutics (PYC) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PYC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield9.46%Price TargetN/A Stock AnalysisStock Analysis Get PYC Therapeutics alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About PYC TherapeuticsPYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 PYC Stock News HeadlinesAugust 11, 2023 | finance.yahoo.comUS FDA DESIGNATES PYC'S LEAD AS A FAST TRACK DEVELOPMENT PROGRAMJuly 24, 2023 | au.finance.yahoo.comPYC.AX - PYC Therapeutics LimitedApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinJuly 17, 2023 | msn.comASX Health Stocks: Successful toxicology tests pave the way for PYC’s Phase 2 clinical trialJuly 15, 2023 | finance.yahoo.comNon-Executive Chair of the Board of PYC Therapeutics Alan Tribe Buys 26% More SharesMarch 5, 2023 | msn.comASX Health Stocks: Rhythm crashes 45pc after withdrawing TGA application for ColoSTATJanuary 13, 2023 | finance.yahoo.comOwning 50% in PYC Therapeutics Limited (ASX:PYC) means that insiders are heavily invested in the company's futureDecember 23, 2022 | nz.finance.yahoo.comPYC Therapeutics Limited (ASX:PYC) insider upped their holding by 0.2% earlier this yearApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinNovember 22, 2022 | finance.yahoo.comWill PYC Therapeutics (ASX:PYC) Spend Its Cash Wisely?September 14, 2022 | finance.yahoo.comPYC Therapeutics Limited (PYC.AX)August 16, 2022 | reuters.comPYC Therapeutics LtdAugust 8, 2022 | nz.finance.yahoo.comAHF Sounds ‘Monkeypox: LA County Alert’ in Latest LA Times AdAugust 8, 2022 | nz.finance.yahoo.comBond Traders on Collision Course With Fed Over Longer-Term ViewJune 7, 2022 | finance.yahoo.comWe're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash WiselyMay 9, 2022 | finance.yahoo.comThose who invested in PYC Therapeutics (ASX:PYC) three years ago are up 256%March 2, 2022 | news.yahoo.comHow to Increase the Competitive Advantage of Your Small to Midsize BusinessMarch 1, 2022 | news.yahoo.comKillearn Golf & Country Club on verge of new ownership, 'massive revitalization' on horizonFebruary 27, 2022 | finance.yahoo.comWhat Is The Ownership Structure Like For PYC Therapeutics Limited (ASX:PYC)?February 23, 2022 | lse.co.ukShield Thera Share ChatJanuary 24, 2022 | msn.comBritain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized PatientsDecember 30, 2021 | finance.yahoo.comPYC Therapeutics Limited (ASX:PYC) insider upped their holding by 0.06% earlier this yearNovember 15, 2021 | finance.yahoo.comCompanies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In GrowthSee More Headlines Receive PYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PYC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PYC CUSIPN/A CIKN/A Webpyctx.com Phone61 8 6151 0992FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,650,000.00 Net Margins-101.90% Pretax MarginN/A Return on Equity-80.66% Return on Assets-38.38% Debt Debt-to-Equity Ratio1.77 Current Ratio3.98 Quick Ratio8.93 Sales & Book Value Annual Sales$21.24 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares4,230,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.63 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Rohan Hockings G.D.L.P (Age 41)J.D., MBBS, MBBS (Hons.), CEO & Executive Director Comp: $437.5kMr. Andrew Taylor B.Com.C.A., CFO & Company SecretaryMr. Kevin Ronald Hart B.Com. (Age 62)B.Comm (Hons), C.A., F.C.A., Company Secretary Comp: $165.9kKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersAlan TribeSold 307,453,493 sharesTotal: $24.60 M ($0.08/share)Rohan HockingsSold 18,181,818 sharesTotal: $1.82 M ($0.10/share)Alan TribeSold 254,545,459 sharesTotal: $14.00 M ($0.06/share)Rohan HockingsSold 18,181,818 sharesTotal: $999,999.99 ($0.06/share)Alan TribeBought 82,610 shares on 6/29/2023Total: $4,378.33 ($0.05/share) This page (ASX:PYC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PYC Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
